Ascentage Pharma’s 17 Advances at EHA 2026
Decision brief
Answer first · skim in under a minute
Ascentage Pharma is set to present 17 clinical advances at the 2026 European Hematology Association Congress, marking a pivotal moment for the company. This presentation could influence investment decisions and competitive strategies in the hematology sector.
Ascentage Pharma’s EHA 2026 presence is a concrete hematology catalyst, not a vague pipeline tease. The company said 17 clinical advances—including 8 posters—were selected for the Stockholm congress on June 11–14, 2026.
Contents9 sections
Key Takeaways
- Ascentage reported 17 clinical advances accepted for EHA2026, with 8 poster presentations.
- EHA2026 ran June 11–14, 2026 in Stockholm, Sweden.
- Featured assets include olverembatinib (HQP1351) and lisaftoclax (APG-2575).
- Updates span CML, Ph+ ALL (including POLARIS-1 Part 1), and CLL/SLL datasets.
What did Ascentage announce for EHA 2026?
On May 12–13, 2026, Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) said 17 clinical advances of its core assets would be featured at the 31st Congress of the European Hematology Association.
The release specifies eight poster presentations covering ongoing studies of olverembatinib and lisaftoclax. Source: GlobeNewswire May 2026 EHA acceptance release.
Which clinical programs are in the abstract set?
Accepted poster titles highlighted in the company wire include second-line olverembatinib in chronic-phase CML, activity after ponatinib or asciminib resistance with ASXL1 mutations, and updated POLARIS-1 Part 1 Phase 3 results in newly diagnosed Ph+ ALL.
- Olverembatinib ± chemotherapy or combinations in Ph+ ALL
- Lisaftoclax baseline-to-prognosis analyses in CLL/SLL Phase 2
- Pediatric olverembatinib plus lisaftoclax Phase 1b safety/efficacy signals
A follow-up wire after the meeting reiterated that seventeen clinical updates were presented at EHA2026: GlobeNewswire June 14, 2026 EHA update.
Why do these data matter for European BD teams?
EHA is a primary European hematology venue where global registrational narratives meet EU KOLs. Olverembatinib’s China approvals do not equal EU authorisation, so abstracts are diligence inputs, not labels.
Partnering teams should map each abstract to study phase, geography, comparator, and whether the endpoint is regulatory-grade or exploratory. Competitive context includes other third-generation BCR-ABL and Bcl-2 strategies already established in Western markets.
Competitive intelligence teams should also note ticker identifiers used in the wires—NASDAQ: AAPG and HKEX: 6855—when tying congress catalysts to equity liquidity and follow-on financing windows after major hematology meetings.
How should investors separate signal from noise?
Abstract selection shows pipeline breadth. It does not prove EU filing readiness or commercial uptake.
Prioritize randomized or registrational datasets such as POLARIS-1 updates over early combination or real-world posters when building models. Confirm later peer-reviewed publications before treating response rates as durable.
For trial-method context on hematologic malignancies more broadly, ASCO educational materials remain a useful clinical reference frame: ASCO homepage.
What remains unproven after EHA 2026?
Company wires summarize selected abstracts; they are not a substitute for full posters, protocols, or independent statistical review. Cross-trial comparisons to ponatinib, asciminib, or venetoclax regimens require matched populations.
No EU marketing authorisation for olverembatinib or lisaftoclax should be inferred from congress presentation counts alone.
Related NovaPharma coverage
- EMEA 2026 life sciences cluster report
- EU clinical trial recruitment consent template
- Maersk Europe June 2026 pharma supply chains
Frequently Asked Questions
How many Ascentage clinical advances were selected for EHA 2026?
Ascentage Pharma announced that 17 clinical advances from its core assets would be featured at the 31st European Hematology Association Congress (EHA2026), including 8 poster presentations.
When and where was EHA2026 held?
According to Ascentage’s GlobeNewswire release, EHA2026 convened in Stockholm, Sweden, from June 11 to 14, 2026.
Which Ascentage assets dominated the EHA 2026 abstracts?
Company releases highlight olverembatinib (HQP1351), a third-generation BCR-ABL inhibitor approved in China, and lisaftoclax (APG-2575), a China-developed Bcl-2 selective inhibitor, across CML, Ph+ ALL, and CLL/SLL datasets.
Primary Sources
Ascentage Pharma pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
